Journal
SCIENCE ADVANCES
Volume 6, Issue 27, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.aba7443
Keywords
-
Categories
Funding
- MUSC
- NCI [R01 CA175061, R01 CA 208514, F30 CA243307, T32 GM008716, T32 DE017551, F31 CA192787, R50 CA233186, R01 CA222817]
- American Cancer Society IRG [016623-004]
- KL2 [UL1 TR000062]
- Jeane B. Kempner Postdoctoral Fellowship
- American Cancer Society [122704-PF-13-084-01-LIB]
- NIH [T32 GM008716, F30 CA200272]
- Hollings Cancer Center Flow Cytometry Cell Sorting
- Genomics Shared Resource [P30 CA138313]
Ask authors/readers for more resources
How naturally arising human CD4(+) T helper subsets affect cancer immunotherapy is unclear. We reported that human CD4(+)CD26(high) T cells elicit potent immunity against solid tumors. As CD26(high) T cells are often categorized as T(H)17 cells for their IL-17 production and high CD26 expression, we posited these populations would have similar molecular properties. Here, we reveal that CD26(high) T cells are epigenetically and transcriptionally distinct from T(H)17 cells. Of clinical importance, CD26(high) and T(H)17 cells engineered with a chimeric antigen receptor (CAR) regressed large human tumors to a greater extent than enriched T(H)1 or T(H)2 cells. Only human CD26(high) T cells mediated curative responses, even when redirected with a suboptimal CAR and without aid by CD8(+) CART cells. CD26(high) T cells cosecreted effector cytokines, produced cytotoxic molecules, and persisted long term. Collectively, our work underscores the promise of CD4(+) T cell populations to improve durability of solid tumor therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available